6 news items
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP
3 Jun 24
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
ABEO
ADAP
INBS
31 May 24
(TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
ADAP
31 May 24
in head & neck cancer.
Uza-cel, which has shown an 80% response rate in a Phase 1 trial
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date
v9dy x1xniqg
ADAP
GLPG
30 May 24
Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1
- Prev
- 1
- Next